NASDAQ$BCAB
Bioatla Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2024, and provided highlights on its clinical programs.
BioAtla reported a net loss of $10.6 million for Q3 2024, including $11.0 million in collaboration revenue. The company's cash and cash equivalents were $56.5 million as of September 30, 2024, expected to fund operations into early 2026. They are advancing clinical programs and received positive FDA feedback, positioning them for potential registrational trials in 2025.
- Ozuriftamab vedotin Phase 2 trial in SCCHN demonstrates durable clinical responses and median OS of approximately 9 months in a heavily pretreated population; actionable FDA feedback received regarding pivotal trial in 2L plus SCCHN
- Evalstotug in combination with PD-1 demonstrates tumor reduction in all eight, first-line unresectable or metastatic melanoma patients with 4 responses including a complete response (CR), ongoing, with relatively low incidence and severity of immune-related adverse events; FDA guidance received on ongoing dose optimization and control arm anticipated to enable Phase 3 trial
- Mecbotamab vedotin Phase 2 trial in NSCLC shows tumor reduction across nine different mutant KRAS variants; an improved median OS of 12.6 months, ongoing, among treated patients with tumors expressing mKRAS variants compared to KRAS wildtype
- Recent worldwide license agreement for preclinical CAB-Nectin-4 bispecific T-cell engager; current cash balance now projected to fund operations into early 2026
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$11M
Forward guidance
BioAtla anticipates reducing operating expenses and is positioned for potential registrational trials. They expect current cash and cash equivalents to fund planned operations into early 2026 and maintain near-term guidance for a strategic collaboration with at least one of their Phase 2 assets.
Tailwinds
- Current cash and cash equivalents expected to fund planned operations into early 2026.
- Completing dose optimization for CAB-ROR2 and CAB-CTLA4.
- Positioning CAB-ROR2 and CAB-CTLA4 programs for potentially registrational trials.
- Maintaining near-term guidance for a strategic collaboration with at least one of P2 assets.
- Expecting to further reduce operating expense in the coming quarters.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro